Sterling Bay Partnership Secures $290M Financing for Sorrento Mesa’s Pacific Center

Why It Matters

The financing signals robust investor appetite for life‑science real estate, a sector driving regional biotech growth. It also provides Pacific Center with the capital needed to attract and retain innovative tenants, bolstering San Diego’s position as a biotech hub.

Key Takeaways

• $290M refinancing completed for Pacific Center, San Diego
• Includes $162.5M future funding for leasing and carry reserves
• 525,000 sq ft Class A life‑science campus ready for R&D tenants
• Financing led by Newmark, Peregrine Capital, Sterling Bay JV
• Highlights lender confidence in life‑science asset class

Pulse Analysis

Life‑science real estate has become a magnet for capital as biotech firms seek purpose‑built campuses that blend laboratory space with collaborative environments. San Diego’s Sorrento Mesa, already a cluster of research institutions, benefits from the addition of Pacific Center, a 525,000‑square‑foot Class A campus designed to accommodate everything from early‑stage R&D to full‑scale production. The region’s talent pool, proximity to universities, and supportive ecosystem make it an attractive destination for both domestic and foreign investors seeking long‑term, inflation‑hedged returns.

The $290 million refinancing, anchored by $162.5 million of forward‑looking funding, provides Pacific Center with a financial cushion to offer tenant improvement allowances and cover operating carry costs during lease‑up. Newmark’s Global Debt & Structured Finance team structured the deal, while Peregrine Capital supplied the capital, reflecting a growing partnership model where real‑estate sponsors align with specialist lenders to de‑risk large‑scale projects. This financing approach not only reduces the sponsor’s balance‑sheet exposure but also signals to the market that institutional capital is willing to back high‑quality, purpose‑built life‑science assets.

For the broader commercial‑real‑estate market, the transaction illustrates a shift toward sector‑specific financing, where lenders evaluate properties based on tenant pipelines and industry fundamentals rather than generic occupancy metrics. As biotech innovation accelerates, similar campuses are likely to attract comparable capital structures, reinforcing the feedback loop between asset quality, tenant demand, and financing availability. Investors monitoring the life‑science space should note the increasing prevalence of hybrid financing models that blend traditional debt with forward‑funded reserves, a formula that could become a benchmark for future high‑growth, specialized real‑estate projects.